Xcout Intel
AbolerIS Pharma competitors & alternatives
The 12 closest competitors and alternatives to AbolerIS Pharma among biotechnology companies — ranked by similarity to what AbolerIS Pharma actually does, not by market-cap band.
Subscribe to see AbolerIS Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AbolerIS Pharma
AbolerIS Pharma is a pre-clinical stage biotech company founded in Nantes, France, specializing in the development of innovative immunomodulators and advanced biopharmaceuticals for autoimmune conditions.
AbolerIS Pharma at a glance
AbolerIS Pharma is a biotechnology company headquartered in France. It has raised at least $32M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $29M in September 2023. Xcout tracks 9 named people at AbolerIS Pharma, including Ann Meulemans (CEO).
AbolerIS Pharma leadership
- Ann MeulemansCEO
- Tomas Van DyckCFO
- Philippe AlenChief Business Officer (ad intrim)
- Ronald Van BremptCMO
- Carole GuillonneauCo-Founder
- F.-Xavier HubertDr. F.-Xavier Hubert, MD, PhD
3 more named people on record for AbolerIS Pharma, with roles, board committees and tenure — see the full roster →
AbolerIS Pharma funding rounds
At least $32M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $29M | 9 named | |
| — | $3M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 AbolerIS Pharma competitors
Ranked by semantic similarity — how close each company is to AbolerIS Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Canopy Immuno-Therapeutics is a pre-clinical stage biotechnology company based in Haifa, Israel, focused on developing non-immunosuppressive biologics, including Antigen-Drug Conjugates, for antibody-mediated autoimmune conditions.
Similar biotechnology company
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
Similar biotechnology company
AviSia Therapeutics is a clinical-stage biotechnology company headquartered in Amsterdam, Netherlands, pioneering antigen-specific immunotherapies for autoimmune diseases. Established as a spin-off, the company develops targeted treatments to reprogram immune responses.
Similar biotechnology company
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Biotech
Egle Therapeutics SAS is a clinical-stage biotechnology company headquartered in Paris, France, that develops precision medicines designed to modulate regulatory T cells.
Similar biotechnology company
Abcuro, Inc. is a biotechnology company headquartered in Newton, Massachusetts, focused on developing advanced immunotherapies to treat autoimmune diseases and cancer.
Similar biotechnology company
Enthera is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Milan, Italy. The company focuses on developing first-in-class therapeutics for auto-immune disorders and is backed by investors such as Sofinnova Partners and BiovelocITA.
Similar biotechnology company
Plantibodies is a biotechnology company headquartered in Paris, France, specializing in the development of plant-based oral immunotherapies. Designed to act locally in the body, the company's biological innovations aim to revolutionize biologics and healthcare. Plantibodies has raised funding from leading business angel networks to support its early-stage research.
Similar biotechnology company
Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.
Biotech
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Similar biotechnology company
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AbolerIS Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AbolerIS Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →